Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy - Wikidata - awgldk - TriplyDB

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

http://www.wikidata.org/entity/Q24631288

about

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis Pharmacological management of essential thrombocythemia.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.How I treat essential thrombocythemia.Emerging treatments for essential thrombocythemia European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.Genetic-pathologic characterization of myeloproliferative neoplasms.Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.How to manage essential thrombocythemia.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.WHO classification of myeloproliferative neoplasms (MPN): A critical update.Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.Advances and challenges in the management of essential thrombocythemia.How we diagnose and treat essential thrombocythaemia.Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.Myelofibrosis: molecular and cell biological aspects.Myelodysplastic syndromes with bone marrow fibrosis.Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.Prefibrotic myelofibrosis: treatment algorithm 2018

P2860

Q24607513-176BECCD-244E-4251-A892-EE4218E02020 Q26744113-76C2833F-E41D-4D63-9C5E-A796961A4B1D Q26772881-8339106D-1A6B-43AF-9D06-B73499C04FC9 Q34344384-5CF75070-D5EC-44E8-84B9-54F875A598CF Q34370771-DF77E250-28E3-4CD8-9BE8-EC44FC4D425D Q35132271-B1499471-359A-41E0-BEE6-C8E7598F3E3B Q35683853-D8C92ABF-AB3C-4671-915F-6B1A4F0834AF Q35794415-E324865C-2881-42A2-99F3-6CB8430D89DF Q36316145-84D0166C-34F7-41E6-A97C-D0143D092D15 Q36666769-0F9D67EE-CBCA-47CC-B40D-02B313A4A69A Q37067712-8527E949-2ECE-434C-9947-C4A18FFF71CB Q37151437-EF75ADB8-6055-4A02-B728-4F3376D05656 Q37934479-C6F872F2-E913-4BEC-9451-E3844F595B7C Q37952488-A72D77F2-A9B3-4AE8-B9B9-0A83CECE104C Q38014534-6B50E75C-2D93-4C43-935B-4AF0FF9752C8 Q38028927-B9CE8B6A-50CB-44FE-BD7E-0B79F52FFF62 Q38154519-A91C45EF-2844-48CF-8F03-25129120E296 Q38187675-5FCAE4DC-71E2-4D67-BC59-4D85112B0F21 Q38430511-9D4D6FA3-BE0F-431D-A449-D6A929C3CE2C Q38542093-195CD706-8F48-48D2-BB78-75F57BA181D1 Q38606595-A5CD2BF8-A8C7-4015-9836-12E538EA1924 Q38739162-0809EA3A-7C01-4695-A22A-0DD001D12086 Q38753950-05B56AEE-7C86-4095-8087-FE18F3912DE1 Q38816384-512A4548-2F7C-4CBE-BED8-6C8D9B4C01A9 Q38823803-0C33287D-9710-406F-B968-86D740E72F09 Q41103573-294AF631-8C20-4CED-9057-54B6EABC8C5D Q41952793-BB77B8A8-03A0-40E9-B16E-F20F27639674 Q42586754-20F1938E-4B76-49B8-AF67-D48B1BE14B5E Q46525156-2EC9AC2F-4005-43ED-A6D7-15C1B8E732E0 Q46636672-E7B83B6B-C2AC-4FBF-A081-3F2D9CBE894F Q47094379-818A04DB-FE63-49D9-95F0-CB0F0A4FF291 Q48224401-E4EEE013-0E94-4602-8CA2-BF2FBE02D156 Q53111428-4F4CD37E-6408-41C8-85AB-69ADE10D19E3 Q53147519-7A9C3132-B2F4-4895-9B5F-5E0148E20AF9 Q54262553-F135DE35-9D18-448D-99CF-FA85AB9D59D4 Q54357496-4A456B77-854A-48F3-911E-7C81A2E94964 Q58592871-1F793252-C579-4FDB-9210-347871CEAD6E

P2860

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

http://www.wikidata.org/entity/Q24631288

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Reticulin accumulation in esse ...... ce and relationship to therapy

@ast

Reticulin accumulation in esse ...... ce and relationship to therapy

@en

Reticulin accumulation in esse ...... ce and relationship to therapy

@nl

type

label

Reticulin accumulation in esse ...... ce and relationship to therapy

@ast

Reticulin accumulation in esse ...... ce and relationship to therapy

@en

Reticulin accumulation in esse ...... ce and relationship to therapy

@nl

prefLabel

Reticulin accumulation in esse ...... ce and relationship to therapy

@ast

Reticulin accumulation in esse ...... ce and relationship to therapy

@en

Reticulin accumulation in esse ...... ce and relationship to therapy

@nl

P1433

Q24631288-EC3066F7-97A2-4C6D-94C0-395654ACC3CE

P1476

Q24631288-6B3349D2-ED97-4060-BB58-38068B59AA0B

P2093

Q24631288-0CFD72DC-6F05-43C9-B913-53DB313FEBC1

Q24631288-37912116-DB18-4BF8-9B22-DC682C2F2B71

Q24631288-3A8B23CF-FD00-44E3-9088-964911C72E59

Q24631288-5E73E611-C1D2-47A2-ABA5-20C2464D5C5E

Q24631288-9ABE2C59-C00F-4BEB-8100-A821D3E5A96A

Q24631288-9FC64E93-434B-465B-8635-A998D6352CEA

Q24631288-BD3AA6DD-FA17-4B4F-9D16-B9B237608A3F

Q24631288-F12A13C7-F6B7-4BED-A807-83750F837B79

P2860

Q24631288-1E9C2CA2-4620-47F5-A01D-D4F39C7E9A4D

Q24631288-2D6DC0E0-BADE-4D1B-B843-C8674F6A4618

Q24631288-35F67CAF-90FE-4267-B9D1-A76220C26B42

Q24631288-3BA2BE6A-7777-429A-9061-814C4DD3AAA6

Q24631288-3BEAE510-FAD6-40AC-A3B3-84E397CAD91C

Q24631288-45C169E6-DD36-4870-BBF5-54CC3EA981C6

Q24631288-6BD091A5-E47E-44F8-AFF5-BAF4A6277600

Q24631288-6F7A652C-2DA0-4428-B890-7A772E5531CD

Q24631288-85BBF518-FD37-4BE1-9387-DA84F63D1A21

Q24631288-8711030C-8396-4B95-AF5C-0C6E4526A9B5

P304

Q24631288-65FBE2C8-20AF-4A89-91F6-1FC0B1D6AF4E

P31

Q24631288-2D505D43-73F3-4B7D-9B18-399751B6F9A5

P3181

Q24631288-0F7B7A93-F8A9-4216-9C36-28D08523A16D

P356

Q24631288-6BA4DDDA-DDBE-4F49-9465-043EC299CD94

P407

Q24631288-7B522727-9157-4037-BC23-31C4AB05575B

P433

Q24631288-4D800D8B-63D3-40A4-97EC-4F3E8EDA91A7

P478

Q24631288-936A2325-FAB8-446F-B5F6-7146BDD7E5EA

P50

Q24631288-38AD2E8A-D44E-40EC-8A99-228F1A44DF72

P577

Q24631288-6B902905-0376-4FAC-82EC-C3335080C570

P5875

Q24631288-5EDA1BC9-AA90-4A13-9563-ED4FC6B7F683

P698

Q24631288-2CFDE2EB-DAF9-4344-99A2-0021D55AF695

P932

Q24631288-7C5A0583-CFD6-40D8-B1A4-08626CE7F62D

P3181

P356

JCO.2008.20.3174

P1433

Journal of Clinical Oncology

P1476

Reticulin accumulation in esse ...... ce and relationship to therapy

@en

P2093

Anthony R Green

http://www.w3.org/2001/XMLSchema#string

Bridget S Wilkins

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

David Bareford

http://www.w3.org/2001/XMLSchema#string

Georgina Buck

http://www.w3.org/2001/XMLSchema#string

Penny Wright

http://www.w3.org/2001/XMLSchema#string

Peter J Campbell

http://www.w3.org/2001/XMLSchema#string

Wendy N Erber

http://www.w3.org/2001/XMLSchema#string

P2860

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Long-term use of anagrelide in young patients with essential thrombocythemia.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

P304

2991-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4448688

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.20.3174

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24276195

http://www.w3.org/2001/XMLSchema#string

P698

19364963

http://www.w3.org/2001/XMLSchema#string

P932

3398138

http://www.w3.org/2001/XMLSchema#string